The trial’s one-year interim data has shown an overall response rate of 69% and minimised tumour target lesions. Credit: Evgeniy Kalinovskiy/Shutterstock.

Evaxion Biotech has completed subject dosing in the Phase II trial of its personalised peptide-based cancer vaccine, EVX-01, for the treatment of advanced melanoma, also referred to as skin cancer.

The trial, which is evaluating the vaccine in conjunction with MSD’s Keytruda, is progressing and remains on course for a data readout in the second half of this year.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Subjects in the trial received a distinctly designed and manufactured vaccine depending on their biological factors, the company noted.

Developed using the company’s AI-Immunology platform, the vaccine is designed to aim at immune characteristics as well as the ‘unique’  tumour profile of each patient, aiming to involve their immune system to combat cancer.

The trial’s convincing one-year interim data has shown an overall response rate of 69% and minimised tumour target lesions in 15 out of 16 subjects.

The data also revealed a ‘positive’ correlation between the platform’s predictions and the immune responses induced by the neoantigens of the individuals in the vaccine. The vaccine is used as a first-line treatment for multiple advanced solid cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Evaxion Biotech CEO Christian Kanstrup said: “We are happy to report the completion of the dosing in this important trial, demonstrating our strong capabilities in trial execution.

“Based on the impressive data generated so far, we see that EVX-01 could potentially become a new and effective treatment option for advanced melanoma. With more than 300,000 new melanoma cases each year and significant medical needs, this offers great commercial potential for Evaxion.”

Previously, a Phase I/IIa trial of the vaccine combined with a programmed cell death protein 1 (PD-1) inhibitor showed that eight out of 12 metastatic melanoma subjects experienced objective clinical responses, with vaccine-induced T cells identified in all subjects.